Physician profile
Sara E Taylor
NPI 1225475296
$2,491.72
in general payments reported to CMS, 2019-2025
31 companies · $22.97 in 2025
The $22.97 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $682 · 2022: $780 · 2023: $962 · 2024: $46.12 · 2025: $22.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,030.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.13 | 2021-2024 | |
| Lilly USA, LLC | $200.25 | 2021-2023 | Mounjaro, Emgality, Reyvow |
| Takeda Pharmaceuticals U.S.A., INC. | $184.79 | 2021-2023 | Trintellix, Gattex |
| Amgen INC. | $177.86 | 2021-2023 | Evenity, Prolia |
| Novo Nordisk INC | $166.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $129.79 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $100.98 | 2022-2023 | Jornay Pm |
| Mylan Specialty L.P. | $88.88 | 2021-2022 | |
| Astellas Pharma US INC | $75.81 | 2021-2023 | Myrbetriq, Veozah |
| Otsuka America Pharmaceutical, INC. | $75.54 | 2021-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $67.96 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $66.96 | 2021-2023 | |
| Astrazeneca Pharmaceuticals Lp | $60.73 | 2021-2023 | Farxiga |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.90 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $58.88 | 2021-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $58.56 | 2023 | Cologuard Collection Kit |
| Abbott Laboratories | $50.52 | 2021-2023 | Freestyle Libre 3 |
| Pfizer INC. | $49.43 | 2023 | |
| Agile Therapeutics, INC. | $46.87 | 2022 | |
| Corium, LLC | $37.04 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.42 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.71 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $28.42 | 2023 | Auvelity |
| Aimmune Therapeutics, INC. | $26.91 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.64 | 2021 | |
| Sanofi Pasteur INC. | $18.51 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.22 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.94 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.79 | 2022 | |
| Currax Pharmaceuticals LLC | $13.28 | 2022 | |
| Philips North America LLC | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.